Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHSE:600513) agreed to acquire an additional 6.5% stake in Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd. from Qian Wangni, Yu Tongfu, Cheng Qi and Fu Shunyou for CNY 0.36 million on March 24, 2017. Under the terms of transaction, Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd. will acquire 2% stake from Qian Wangni for CNY 0.11 million, 1.5% stake from Yu Tongfu for CNY 0.08 million, 1.5% stake from Cheng Qi for CNY 0.08 million and 1.5% stake from Fu Shunyou for CNY 0.08 million. For the year ended December 31, 2016, Yangzhou Lianhuan Pharmaceutical Marketing Co., Ltd. reported revenue of CNY 109.7 million, total assets of CNY 55.7 million, operating loss of CNY 0.34 million, net loss of CNY 0.31 and total common equity of CNY 2.86 million. The transaction is not subject to approval by shareholders of Jiangsu Lianhuan Pharmaceutical Co., Ltd. approval. The transaction has been approved by Board of Jiangsu Lianhuan Pharmaceutical Co., Ltd.